274 related articles for article (PubMed ID: 23559009)
1. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression.
Wang W; Cheng B; Miao L; Mei Y; Wu M
Cell Death Dis; 2013 Apr; 4(4):e574. PubMed ID: 23559009
[TBL] [Abstract][Full Text] [Related]
2. Post-transcriptional regulation of the tumor suppressor p53 by a novel miR-27a, with implications during hypoxia and tumorigenesis.
Maqbool R; Lone SN; Ul Hussain M
Biochem J; 2016 Oct; 473(20):3597-3610. PubMed ID: 27531966
[TBL] [Abstract][Full Text] [Related]
3. Coordinated targeting of the EGFR signaling axis by microRNA-27a*.
Wu X; Bhayani MK; Dodge CT; Nicoloso MS; Chen Y; Yan X; Adachi M; Thomas L; Galer CE; Jiffar T; Pickering CR; Kupferman ME; Myers JN; Calin GA; Lai SY
Oncotarget; 2013 Sep; 4(9):1388-98. PubMed ID: 23963114
[TBL] [Abstract][Full Text] [Related]
4. NFAT5 is Regulated by p53/miR-27a Signal Axis and Promotes Mouse Ovarian Granulosa Cells Proliferation.
Tao H; Xiong Q; Ji Z; Zhang F; Liu Y; Chen M
Int J Biol Sci; 2019; 15(2):287-297. PubMed ID: 30745821
[TBL] [Abstract][Full Text] [Related]
5. EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53.
Kapoor GS; Christie A; O'Rourke DM
Cancer Biol Ther; 2007 Apr; 6(4):571-9. PubMed ID: 17457042
[TBL] [Abstract][Full Text] [Related]
6. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
7. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7.
Webster RJ; Giles KM; Price KJ; Zhang PM; Mattick JS; Leedman PJ
J Biol Chem; 2009 Feb; 284(9):5731-41. PubMed ID: 19073608
[TBL] [Abstract][Full Text] [Related]
8. Mutation R273H confers p53 a stimulating effect on the IGF-1R-AKT pathway via miR-30a suppression in breast cancer.
Guo F; Chen H; Chang J; Zhang L
Biomed Pharmacother; 2016 Mar; 78():335-341. PubMed ID: 26898459
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 exerts oncogenic effects through microRNAs and their target gene networks.
Li XL; Jones MF; Subramanian M; Lal A
FEBS Lett; 2014 Aug; 588(16):2610-5. PubMed ID: 24726728
[TBL] [Abstract][Full Text] [Related]
10. Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer.
Chari NS; Ivan C; Le X; Li J; Mijiti A; Patel AA; Osman AA; Peterson CB; Williams MD; Pickering CR; Caulin C; Myers JN; Calin GA; Lai SY
J Natl Cancer Inst; 2020 Mar; 112(3):266-277. PubMed ID: 31124563
[TBL] [Abstract][Full Text] [Related]
11. Hotspot mutant p53-R273H inhibits KLF6 expression to promote cell migration and tumor metastasis.
Sun S; Chen H; Sun L; Wang M; Wu X; Xiao ZJ
Cell Death Dis; 2020 Jul; 11(7):595. PubMed ID: 32733026
[TBL] [Abstract][Full Text] [Related]
12. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.
Gunaratne PH; Pan Y; Rao AK; Lin C; Hernandez-Herrera A; Liang K; Rait AS; Venkatanarayan A; Benham AL; Rubab F; Kim SS; Rajapakshe K; Chan CK; Mangala LS; Lopez-Berestein G; Sood AK; Rowat AC; Coarfa C; Pirollo KF; Flores ER; Chang EH
Cancer; 2019 Jul; 125(14):2409-2422. PubMed ID: 31012964
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.
Dong P; Xu Z; Jia N; Li D; Feng Y
Mol Cancer; 2009 Nov; 8():103. PubMed ID: 19917135
[TBL] [Abstract][Full Text] [Related]
14. Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells.
Pires MM; Hopkins BD; Saal LH; Parsons RE
Cancer Biol Ther; 2013 Mar; 14(3):246-53. PubMed ID: 23291982
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-7 Compromises p53 Protein-dependent Apoptosis by Controlling the Expression of the Chromatin Remodeling Factor SMARCD1.
Hong CF; Lin SY; Chou YT; Wu CW
J Biol Chem; 2016 Jan; 291(4):1877-1889. PubMed ID: 26542803
[TBL] [Abstract][Full Text] [Related]
16. microRNA-27a functions as a tumor suppressor in esophageal squamous cell carcinoma by targeting KRAS.
Zhu L; Wang Z; Fan Q; Wang R; Sun Y
Oncol Rep; 2014 Jan; 31(1):280-6. PubMed ID: 24154848
[TBL] [Abstract][Full Text] [Related]
17. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
Lee SY; Shin SJ; Kim HS
Int J Oncol; 2013 Mar; 42(3):1027-35. PubMed ID: 23314357
[TBL] [Abstract][Full Text] [Related]
18. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours.
Mastropasqua F; Marzano F; Valletti A; Aiello I; Di Tullio G; Morgano A; Liuni S; Ranieri E; Guerrini L; Gasparre G; Sbisà E; Pesole G; Moschetta A; Caratozzolo MF; Tullo A
Mol Cancer; 2017 Mar; 16(1):67. PubMed ID: 28327152
[TBL] [Abstract][Full Text] [Related]
19. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.
Amir S; Ma AH; Shi XB; Xue L; Kung HJ; Devere White RW
PLoS One; 2013; 8(4):e61064. PubMed ID: 23585871
[TBL] [Abstract][Full Text] [Related]
20. Med19 is targeted by miR-101-3p/miR-422a and promotes breast cancer progression by regulating the EGFR/MEK/ERK signaling pathway.
Zhang X; Gao D; Fang K; Guo Z; Li L
Cancer Lett; 2019 Mar; 444():105-115. PubMed ID: 30583076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
